Current Month
Article Features
  A Master Switch Controls Aggressive Breast Cancer
Back to the Future: Breast Cancer Reprises Pathways Found in Fetal Cells
Breast Cancer Surgery in Frail Elderly Women Linked to Poor Results
Breast Cancers Enlist the Help of Normal Cells to Spread and Survive
Breast Tissue Tumor Suppressor PTEN: A Potential Achilles Heel for Breast Cancer Cells
Does Chemotherapy Harm Ability to Function for Older Women with Breast Cancer?
First Study on Physical Properties of Giant Cancer Cells May Inform New Treatments
Investigating What Keeps Metastatic Breast Cancer in Check
Living Close to Urban Green Spaces is Associated with a Decreased Risk of Breast Cancer
Mammography Screening Also Confers Benefits on Participants with Interval Cancer
Medically Underserved Women in the Southeast Rarely Receive BRCA Tests
PARP Inhibitor Improves Progression-Free Survival in Patients with Advanced Breast Cancers
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
Prioritizing Cardiac Monitoring for High-Risk Breast Cancer Patients
Research Team Identifies Genes That Increase Risk for Triple-Negative Breast Cancer
Researchers Identify a Potential New Approach to Treat HER2 Positive Breast Cancer
Sequencing Genomes of Nigerian Women Could Help Prevent Many Lethal Breast Cancers
The Long-Term Financial Toll of Breast Cancer

The Long-Term Financial Toll of Breast Cancer

The financial fallout from breast cancer can last years after diagnosis, particularly for those with lymphedema, a common side effect from treatment, causing cumulative and cascading economic consequences for survivors, their families, and society, a study led by Johns Hopkins Bloomberg School of Public Health researchers suggests.

Excluding productivity costs, those with lymphedema were estimated to have an average of $2,306 in out-of-pocket costs per year, compared to $1,090 for those without lymphedema a difference of 112%, the study found. When factoring in productivity costs, those with lymphedema spent an average of $3,325 in out-of-pocket costs, compared to $2,792 for those without lymphedema.

"That extra $2,000 or so may not break the bank in one year," says study leader Lorraine T. Dean, ScD, assistant professor in the Department of Epidemiology at the Bloomberg School. "But it can take away discretionary spending, or whittle away retirement savings. If it's a recurring burden each year, how can you ever rebuild? That extra $2,000 in spending can cripple people over the long term."

The findings, published in the journal Supportive Care in Cancer, are a call to action for policymakers to develop new ways to curb costs after cancer, the authors say.

Read More of the Main Article

Visit the Ezine

Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon